Here’s How Many Shares of Coca-Cola You Must Own to Get $5,000 in Yearly Dividends

Formed in 1886, Coca-Cola (KO -1.09%) has become a household name by marketing and selling its large portfolio of beverages (including its namesake soft drink) around the world.

Beyond its popularity with consumers, however, Coca-Cola has also long been a favorite in the stock market too, thanks to its steady growth and long history of paying dividends. For investors targeting $5,000 in dividend income each year, here’s how many shares of Coca-Cola stock you would have to own.

Two people sipping sodas.

Image source: Getty Images.

Not just any dividend stock but a Dividend King

Coca-Cola certainly has an unwavering commitment to its dividend. Not only has the company kept up its regular payments, but it has raised them annually for more than six decades. That makes Coca-Cola a Dividend King.

The board of directors ran the payout growth streak to 63 straight years after it increased the dividend earlier this year to a quarterly rate of $0.51 per share. The new rate started with April’s payout.

It doesn’t look like Coca-Cola has a problem affording the higher dividend, either. The company has a payout ratio of 77%, meaning its dividend payouts over the past 12 months have added up to about three-quarter’s of the company’s net income from that period.

A market-beating dividend yield

With the company’s commitment and ability to pay dividends settled, it’s time to turn your attention to the share count needed to collect $5,000 yearly.

Coca-Cola’s current $0.51 dividend works out to $2.04 per year, so 2,451 shares would be necessary to receive $5,000 total. Based on the June 13 closing price of $71.02, you’d need to invest $174,070 to own that many shares.

Given the company’s track record, remember your annual dividend income should increase every year, and shareholders also receive a higher dividend yield compared to the broad market. Coca-Cola stock yields 2.9% versus the S&P 500 index’s 1.3%.

Source link

Visited 1 times, 1 visit(s) today

Related Article

Minnesota Rep. Melissa Hortman and Sen. John Hoffman.

How the attacks on two Minnesota lawmakers unfolded

Facebook Tweet Email Link It was about 3:35 a.m. Saturday when Brooklyn Park police approached the home of former Minnesota House Speaker Melissa Hortman. Instinct had led them there, spurred by a 911 call 90 minutes earlier from the daughter of state Sen. John Hoffman. A masked man had come to the door of their

Local walkers raise more than £20,000 for Parkinson’s UK

Local walkers raise more than £20,000 for Parkinson’s UK

363 walkers took part in their local Walk for Parkinson’s event at Mote Park in Maidstone, raising more than £20,000 for Parkinson’s UK. All the money raised will go towards the charity’s new Nurse Appeal, which is aiming to raise £9m to fund Parkinson’s nurses and other specialists. Parkinson’s specialists are a lifeline for the 153,000 people in the UK living

A person looking at a computer.

Should You Forget Palantir and Buy These 2 Tech Stocks Instead?

Palantir Technologies (NASDAQ: PLTR) has emerged as a leading artificial intelligence company, offering AI data analytics to the U.S. government and businesses. And the company is growing quickly, with sales rising 39% to $884 million and adjusted earnings increasing 63% to $0.13 per share in the first quarter. That second figure is especially notable because

NXP Semiconductors’ (NASDAQ:NXPI) Dividend Will Be $1.01

NXP Semiconductors N.V. (NASDAQ:NXPI) will pay a dividend of $1.01 on the 9th of July. The dividend yield will be 1.9% based on this payment which is still above the industry average. Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit. If the

Sarepta and Roche halt DMD gene therapy’s use after second death  

Sarepta and Roche halt DMD gene therapy’s use after second death  

Elevidys is the only gene therapy approved in US for DMD. Dragon Claws via Shutterstock. Serepta and global partner Roche have discontinued the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) in non-ambulatory patients after a safety profile re-assessment following two patient deaths. Roche said that the dosing restrictions

0
Would love your thoughts, please comment.x
()
x